A New Method Based on LAMP-CRISPR–Cas12a-Lateral Flow Immunochromatographic Strip for Detection
Huaming Xu,Hao Tang,Rongrong Li,Zhaoxin Xia,Wensu Yang,Yi Zhu,Zhen Liu,Guoping Lu,Shenwang Ni,Jilu Shen
DOI: https://doi.org/10.2147/IDR.S348456
2022-02-27
Infection and Drug Resistance
Abstract:Huaming Xu, 1 Hao Tang, 2 Rongrong Li, 3 Zhaoxin Xia, 2 Wensu Yang, 2 Yi Zhu, 2 Zhen Liu, 2 Guoping Lu, 4 Shenwang Ni, 2 Jilu Shen 1 1 Department of Laboratory Medicine, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, 230012, People's Republic of China; 2 University Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, 230012, People's Republic of China; 3 The First Affiliated Hospital of Anhui Medical University Laboratory Department, Hefei, Anhui, Peoples' Republic of China; 4 Laboratory Department of Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, Anhui, People's Republic of China Correspondence: Jilu Shen, Tel +86 151 5515 2963, Email ; Introduction: Carbapenemase-mediated antimicrobial resistance is currently a hot spot of global concern. Carbapenem-resistant organisms are highly prevalent in hospitals associated with difficult-to-treat infections, resulting in poor clinical outcome due to limited treatment options. It is urgently needed to have a rapid, efficient, and convenient molecular assay for identifying such resistant strains. Methods: For this end, we developed a new laboratory assay targeting Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM) based on loop-mediated isothermal amplification, CRISPR–Cas12a, and lateral flow immunochromatographic strip (CRISPR–Cas-LAMP-lateral flow strip). The method was designed to use a guide RNA (gRNA) to recognize the target DNA and guide Cas12a to cleave the target DNA, and simultaneously cleave any single-stranded DNA within the cleavage reaction system. Results: The cleavage products are visible to the naked eye on the lateral flow strip. This method is highly sensitive in direct detection of bacteria in samples containing at least 3× 10 5 CFU/mL without the need for bacterial culture. Discussion: It provides shorter turnaround time and higher specificity than the conventional bacterial culture and susceptibility testing method. This new assay is applicable for extensive use in hospital infection control, as well as identification and treatment of resistant strains due to simple operation and inexpensive apparatuses. Keywords: carbapenemase, Klebsiella pneumoniae carbapenemase, New Delhi metallo-β-lactamase, loop-mediated isothermal amplification, CRISPR–Cas12a, lateral flow immunochromatographic strip, detection About 700,000 people die from "superbugs" globally every year. Antibiotic abuse is the culprit of extensive spread of superbugs. Currently, carbapenemase-producing organisms are among the most important pathogens of hospital infections. Especially the plasmid-mediated highly transmissible carbapenem-resistant Enterobacterales (CRE) has become an important public health issue of global concern. Carbapenemases are a broad category of beta-lactamases which can hydrolyze nearly all beta-lactam antibiotics, including carbapenems. Carbapenemases are primarily classified into Ambler classes A, B, and D. The infections caused by such carbapenem-resistant organisms usually also resist other commonly used antimicrobial agents, resulting in the dilemma of no effective drug available in clinical practice. Antibiotic-resistant infections are associated with longer hospital stay and higher medical expenses and mortality. Since Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae was reported for the first time in 2001, KPC-producing Enterobacterales have been spreading extensively, and resulted in outbreaks across the world. It has been reported that carbapenemase-producing Enterobacterales have been identified in more than 10 European, American, and Asian countries. However, the lack of a rapid, convenient, and accurate molecular diagnostic assay has hampered the response of public health services to the rapid spread of drug-resistant bacteria. Currently, two categories of laboratory tests (phenotypic assays and molecular tests) are available for detecting carbapenemases in clinical settings. Conventional methods include the disk diffusion method, modified carbapenem inactivation method (mCIM) combined with EDTA-modified carbapenem inactivation test (eCIM), modified Hodge test (MHT), polymerase chain reaction (PCR), and sequencing analysis. These assays are reliable but associated with shortcomings such as a high rate of false-positive results, longer turnaround time (TAT), higher cost, and complex operating procedures. These limitations usually result in delayed laboratory reports of CRE, which not only encourage the clinicians to prescribe expensive antimicrobial therapy empirically, bu -Abstract Truncated-
pharmacology & pharmacy,infectious diseases